Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data
Top Cited Papers
- 1 April 2002
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Pharmacogenetics
- Vol. 12 (3), 251-263
- https://doi.org/10.1097/00008571-200204000-00010
Abstract
The discovery of six distinct polymorphisms in the genetic sequence encoding for the cytochrome P450 2C9 (CYP2C9) protein has stimulated numerous investigations in an attempt to characterize their population distribution and metabolic activity. Since the CYP2C9*1, *2 and *3 alleles were discovered first, they have undergone more thorough investigation than the recently identified *4, *5 and *6 alleles. Population distribution data suggest that the variant *2 and *3 alleles are present in approximately 35% of Caucasian individuals; however, these alleles are significantly less prevalent in African-American and Asian populations. In-vitro data have consistently demonstrated that the CYP2C9*2 and *3 alleles are associated with significant reductions in intrinsic clearance of a variety of 2C9 substrates compared with CYP2C9*1; however, the degree of these reductions appear to be highly substrate-dependent. In addition, multiple in-vivo investigations and clinical case reports have associated genotypes expressing the CYP2C9*2 and *3 alleles with significant reductions in both the metabolism and daily dose requirements of selected CYP2C9 substrates. Individuals expressing these variant genotypes also appear to be significantly more susceptible to adverse events with the narrow therapeutic index agents warfarin and phenytoin, particularly during the initiation of therapy. These findings have subsequently raised numerous questions regarding the potential clinical utility of genotyping for CYP2C9 prior to initiation of therapy with these agents. However, further clinical investigations evaluating the metabolic consequences in individuals expressing the CYP2C9*2, *3, *4, *5, or *6 alleles are required before large-scale clinical genotyping can be recommended.Keywords
This publication has 70 references indexed in Scilit:
- Extreme warfarin sensitivity in siblings associated with multiple cytochrome P450 polymorphismsAmerican Journal of Hematology, 2001
- Pharmacogenetics of Warfarin Elimination and its Clinical ImplicationsClinical Pharmacokinetics, 2001
- Genetic control of anticoagulationThe Lancet, 1999
- Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complicationsThe Lancet, 1999
- Validation of Methods for CYP2C9 Genotyping: Frequencies of Mutant Alleles in a Swedish PopulationBiochemical and Biophysical Research Communications, 1999
- Limited value of the urinary phenytoin metabolic ratio for the assessment of cytochrome P4502C9 activity in vivoBritish Journal of Clinical Pharmacology, 1996
- Cytochrome P450TB (CYP2C): A major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liverLife Sciences, 1993
- Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactionsChemical Research in Toxicology, 1992
- NORMAL METABOLISM OF DEBRISOQUINE AND THEOPHYLLINE IN A SLOW TOLBUTAMIDE METABOLISERAustralian and New Zealand Journal of Medicine, 1985
- Pharmacogenetics of tolbutamide metabolism in humansDiabetes, 1979